Vaccine News and Research

Latest Vaccine News and Research

InnaVirVax announces Phase I/IIa clinical trial authorization for its VAC-3S HIV vaccine

InnaVirVax, a biopharmaceutical company dedicated to the development of therapeutic and diagnostic solutions in pathologies associated with immune dysregulation, declared today that it has obtained authorization from the French drug agency (AFSSAPS) to start a Phase I/IIa clinical study of its therapeutic vaccine VAC-3S for the treatment of HIV infections. This authorization intervenes only two years and half after the launching of InnaVirVax’s activities.

14 Oct 2011

New insights into how adenovirus triggers an immune response

A Loyola University Chicago Stritch School of Medicine study could lead to improved gene therapies for conditions such as heart disease and cancer as well as more effective vaccines for tuberculosis, malaria and other diseases.

13 Oct 2011

UofL associate professor to create an emergency countermeasure staffing plan

Building on the success of Louisville's response to the 2009 H1N1 influenza pandemic, Ruth Carrico, PhD, plans to use a $250,000 one-year cooperative agreement from the Centers for Disease Control and Prevention (CDC) to create an emergency countermeasure staffing plan that utilizes nursing, pharmacy and public health students.

13 Oct 2011

Three key steps to prevent asthma attacks in children during winter

For most people, the word "autumn" conjures up images of honey crisp apples, pumpkin patches and Halloween. But for many pediatricians, fall also means more patients with asthma flare-ups.

13 Oct 2011

USPTO issues patent to Oragenics' In Vivo Induced Antigen Technology

Florida-based nutraceutical company, Oragenics, Inc., announced today the issuance of patent number 8,034,571 from the United States Patent and Trademark office for In Vivo Induced Antigen Technology.

13 Oct 2011

Breakthrough in the study of chlamydia genetics

A breakthrough in the study of chlamydia genetics could open the way to new treatments and the development of a vaccine for this sexually transmitted disease.

13 Oct 2011

TB rates decline for the first time: WHO report

According to Mario Raviglione, director of the World Health Organization (WHO)'s Stop TB program, for the first time, the number of people infected with tuberculosis (TB) each year is declining. He was speaking at a press conference to release Global Tuberculosis Control 2011, WHO's 16th annual report on TB, which summarizes advances made and challenges ahead. The report features data on TB in nearly 200 countries with treatment results and financing trends.

12 Oct 2011

Study finds experimental vaccine protects monkeys from blinding trachoma

"An attenuated, or weakened, strain of Chlamydia trachomatis bacteria can be used as a vaccine to prevent or reduce the severity of trachoma, the world's leading cause of infectious blindness, suggest findings from a National Institutes of Health (NIH) study in monkeys," an NIH press release reports.

12 Oct 2011

AFFiRiS receives MJFF grant for clinical study of AFFITOPE PD01

The Michael J. Fox Foundation (MJFF) today announced that it has awarded $1.5 million to AFFiRiS AG, a Vienna, Austria-based biotech company, for a clinical study of AFFITOPE PD01, a first-of-its-kind Parkinson's disease (PD) vaccine.

12 Oct 2011

Idera announces new data on novel gene-silencing oligonucleotide technology

Idera Pharmaceuticals, Inc. today presented new data on its novel gene-silencing oligonucleotide (GSO) technology at the Cell Symposium on Regulatory RNAs in Chicago, IL.

12 Oct 2011

Aduro initiates CRS-207 and GVAX Pancreas Cancer Vaccine Phase 2 clinical trial

Aduro BioTech, Inc. announces the treatment of the first patient in the Phase 2 pancreatic cancer clinical trial of the sequential administration of two cancer vaccines: Aduro's CRS-207 and GVAX Pancreas Cancer Vaccine.

11 Oct 2011

WHO reports several large measles outbreaks in Europe, Africa

The WHO reported on Friday "that several large measles outbreaks have continued to spread in the past six months in Europe and Africa, and to a lesser degree in the Americas," the U.N. Media Centre reports.

11 Oct 2011

ImmunoCellular receives U.S. patent allowance for ICT-107 to treat GBM

ImmunoCellular Therapeutics, Ltd., a biotechnology company focused on the development of novel immune-based cancer therapies, announced the allowance of U.S. patent claims related to ICT-107, the Company's dendritic cell based cancer vaccine candidate targeting multiple tumor antigens for the treatment of glioblastoma multiforme.

11 Oct 2011

Awards showcase Australia’s promising future in bio-sciences

The six state winners of the AusBiotech/GSK Student Excellence Awards, announced today, will next week compete for the national biosciences research award at AusBiotech 2011.

10 Oct 2011

Coridon demonstrates 100% protection using DNA HSV-2 vaccine

DNA vaccine development company Coridon Pty Ltd. today announced that it had successfully completed pre-clinical efficacy testing of its prototype Herpes Simplex Virus 2 (HSV-2) vaccine, with outstanding results. The company will now look to progress the program into clinical studies.

10 Oct 2011

Potential vaccine against trachoma

An attenuated, or weakened, strain of Chlamydia trachomatis bacteria can be used as a vaccine to prevent or reduce the severity of trachoma, the world's leading cause of infectious blindness, suggest findings from a National Institutes of Health study in monkeys.

10 Oct 2011

First Edition: October 10, 2011

In today's headlines, reports about the 'super committee's' moving parts and how the fate of the health law may be determined by what happens in 2012.

10 Oct 2011

VGX International, Inovio partner to co-develop SynCon vaccines for hepatitis B and C infections

Inovio Pharmaceuticals, Inc., a leader in the development of synthetic vaccines against cancers and infectious diseases, announced today that it has entered into a product development collaboration agreement with its affiliate, VGX International Inc., to co-develop Inovio's SynCon therapeutic vaccines for hepatitis B and C infections.

10 Oct 2011

NIH awards LSUHSC $9 million grant to develop pneumonia vaccine

Dr. Judd Shellito, Chief of the Section of Pulmonary and Critical Care Medicine at LSU Health Sciences Center New Orleans, has been awarded approximately $9 million in grant funding to develop a vaccine against Pneumocystis, an important cause of pneumonia in people with HIV infection. This potentially fatal illness is the most common serious opportunistic infection in people with HIV.

7 Oct 2011

Gates Foundation accepting nominations for vaccine innovation award

The Bill & Melinda Gates Foundation announced on Thursday that "it is accepting nominations for the first Gates Vaccine Innovation Award to recognize, celebrate, and spur transformative ideas for achieving impact through the delivery of vaccines," according to a Gates Foundation press release.

7 Oct 2011